BioGaia's Direct-Market Pivot Accelerates as EMEA Rebounds

Q2 growth of 12% constant-currency with margin expansion, driven by direct-market buildup and new product launches.

BIOG-B.ST · Earnings Call · 2026-07-17

Direct-Market Strategy Gaining Traction

BioGaia's second quarter of 2026 shows a company executing on a clear strategic shift: moving from distributor partnerships to own direct-market operations. The headline is direct market penetration, which now represents 41% of quarterly sales (45% year-to-date). CEO Theresa Agnew highlighted the momentum: “Our growth excluding currency effects was 12% versus year-ago.” — Theresa Agnew, CEO · 2026-07-17 The company is deliberately investing in new subsidiaries—France, Germany, and Austria were launched as direct markets within the past year—and the payoff is visible in the regional numbers. EMEA sales jumped 21% constant-currency, with France and Poland leading, while the Americas grew 16% on the back of robust adult-product demand. The pivot is not without cost. Sales and marketing expenses rose 2% year-over-year, including a one-time SEK 11.3 million item. But the operating leverage is striking: EBIT margin expanded to 30% (adjusted 33%) from 27% a year ago. CFO Alexander Kotsinas attributed the improvement to controlled OpEx, emphasizing “Our total operating expenses were SEK 189 million versus SEK 186 million, so 2% higher versus one year ago.” — Alexander Kotsinas, CFO · 2026-07-17 The company expects CapEx to rise as it expands manufacturing capacity, but the growth investment is squarely aimed at scaling the direct-market model.

In terms of the direct market percentages, for the quarter, our direct markets are 41% of our growth, year-to-date is 45%.
Theresa Agnew, CEO · 2026-07-17

The strategic logic is straightforward: owning distribution gives BioGaia control over brand building and customer relationships, and the early results confirm the thesis. The Pediatric segment (75% of sales) still drives the base, but the adult segment is accelerating—up 23% constant-currency in Q2, led by Prodentis and Gastrus PURE ACTION.

Innovation: Protectis Plus and Beyond

Product innovation remains a core pillar. The newly launched Protectis Plus—a proprietary combination of strains DSM 17938 and BG-R46—is rolling out gradually due to regulatory hurdles, but CEO Theresa Agnew is confident in its potential. At a U.K. baby show with 30,000 consumers, the product received “very positive feedback” — Theresa Agnew, CEO · 2026-07-17. Meanwhile, the company expanded its skincare line with a face & body lotion and a balm-to-milk body wash, both microbiome-friendly and organic, launched in the U.S. and China. These moves underpin a broader "breakthrough innovation" strategy aimed at markets where probiotics are not yet routine.

Regional Divergence: EMEA Strong, APAC Soft

The one weak spot is Asia Pacific, where sales fell 6% constant-currency, dragged down by order variability in China and South Korea. But management expects a rebound: “We do expect... that our China distributor will increase their orders in Q3 and then larger orders in Q4 as well.” — Theresa Agnew, CEO · 2026-07-17 This is a timing issue, not a structural one, and the company's confidence is high. The U.S. posted record sales in Q2, and the overall trajectory points to a strong second half. With a 30% reported operating margin, a 33% adjusted margin, and a strategy that is clearly working, BioGaia is a name to watch. The shift to direct markets is not just a cost line—it is a competitive moat in the making.